Dolutegravir Interactions with HIV-1 Integrase-DNA: Structural Rationale for Drug Resistance and Dissociation Kinetics

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  DeAnda, Felix ^a   Hightower, Kendra E ^a   Nolte, Robert T ^a   Hattori, Kazunari ^b   Yoshinaga, Tomokazu ^b   Kawasuji, Takashi ^b   Underwood, Mark R ^a  

^a GLAXOSMITHKLINE   (United States)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; INTEGRASE; RALTEGRAVIR; VIRUS DNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; BINDING KINETICS; COMPLEX FORMATION; CONTROLLED STUDY; DISSOCIATION; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MOLECULAR DYNAMICS; MOLECULAR MODEL; MUTATIONAL ANALYSIS; NONHUMAN; STRUCTURE ANALYSIS; WILD TYPE;

DRUG RESISTANCE, VIRAL; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; KINETICS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; NUCLEIC ACID CONFORMATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROVIRUSES;

EID: 84885769347     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077448     Document Type: Article

References (34)

1. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, et al. (2007) Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 46: 125-133. doi:10.1097/QAI.0b013e318157131c. PubMed: 17721395.
2. Molina J-M, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, et al. (2012) Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 12: 27-35. doi:10.1016/S1473-3099(11)70249-3. PubMed: 22015077.
3. Raffi F, Rachlis A, Stellbrink H-J, Hardy WD, Torti C, et al. (2013) Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 381: 735-743. doi:10.1016/S0140-6736(12)61853-4. PubMed: 23306000.
4. Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, et al. (2013) Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother 57: 2654-2663. doi:10.1128/AAC.02568-12. PubMed: 23529738.
5. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, et al. (2008) Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 359: 355-365. doi:10.1056/NEJMoa0708978. PubMed: 18650513.
6. Goethals O, Van Ginderen M, Vos A, Cummings MD, Van Der Borght K, et al. (2011) Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor. Antiviral Res 91: 167-176. doi:10.1016/j.antiviral.2011.05.011. PubMed: 21669228.
7. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, et al. (2011) In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 55: 813-821. doi:10.1128/AAC.01209-10. PubMed: 21115794.
8. Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, et al. (2013) Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 207: 740-748. doi:10.1093/infdis/jis750. PubMed: 23225901.
9. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, et al. (2013) Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 382: 700-708. doi:10.1016/S0140-6736(13)61221-0. PubMed: 23830355.
10. Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, et al. (2011) Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 55: 4552-4559. doi:10.1128/AAC.00157-11. PubMed: 21807982.
11. Chen JC, Krucinski J, Miercke LJ, Finer-Moore JS, Tang AH, et al. (2000) Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc Natl Acad Sci U S A 97: 8233-8238. doi:10.1073/pnas.150220297. PubMed: 10890912.
12. Chen X, Tsiang M, Yu F, Hung M, Jones GS, et al. (2008) Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. J Mol Biol 380: 504-519. doi:10.1016/j.jmb.2008.04.054. PubMed: 18565342.
13. Karki RG, Tang Y, Burke TR Jr, Nicklaus MC, (2004) Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design. J Comput Aid Mol Des 18: 739-760. doi:10.1007/s10822-005-0365-5. PubMed: 16075307.
14. Wang JY, Ling H, Yang W, Craigie R, (2001) Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J 20: 7333-7343. doi:10.1093/emboj/20.24.7333. PubMed: 11743009.
15. Wielens J, Crosby IT, Chalmers DK, (2005) A three-dimensional model of the human immunodeficiency virus type 1 integration complex. J Comput Aid Mol Des 19: 301-317. doi:10.1007/s10822-005-5256-2. PubMed: 16184433.
16. Chen A, Weber IT, Harrison RW, Leis J, (2006) Identification of amino acids in HIV-1 and avian sarcoma virus integrase subsites required for specific recognition of the long terminal repeat Ends. J Biol Chem 281: 4173-4182. doi:10.1074/jbc.M510628200. PubMed: 16298997.
17. Esposito D, Craigie R, (1998) Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. EMBO J 17: 5832-5843. doi:10.1093/emboj/17.19.5832. PubMed: 9755183.
18. Gao K, Butler SL, Bushman F, (2001) Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes. EMBO J 20: 3565-3576. doi:10.1093/emboj/20.13.3565. PubMed: 11432843.
19. Heuer TS, Brown PO, (1998) Photo-cross-linking studies suggest a model for the architecture of an active human immunodeficiency virus type 1 integrase-DNA complex. Biochemistry 37: 6667-6678. doi:10.1021/bi972949c. PubMed: 9578550.
20. Jenkins TM, Esposito D, Engelman A, Craigie R, (1997) Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking. EMBO J 16: 6849-6859. doi:10.1093/emboj/16.22.6849. PubMed: 9362498.
21. Zhao Z, McKee CJ, Kessl JJ, Santos WL, Daigle JE, et al. (2008) Subunit-specific protein footprinting reveals significant structural rearrangements and a role for N-terminal Lys-14 of HIV-1 integrase during viral DNA binding. J Biol Chem 283: 5632-5641. PubMed: 18093980.
22. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P, (2010) Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464: 232-236. doi:10.1038/nature08784. PubMed: 20118915.
23. Hare S, Vos AM, Clayton RF, Thuring JW, Cummings MD, et al. (2010) Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A 107: 20057-20062. doi:10.1073/pnas.1010246107. PubMed: 21030679.
24. Hare S, Smith SJ, Métifiot M, Jaxa-Chamiec A, Pommier Y, et al. (2011) Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol 80: 565-572. doi:10.1124/mol.111.073189. PubMed: 21719464.
25. Krishnan L, Li X, Naraharisetty HL, Hare S, Cherepanov P, et al. (2010) Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc Natl Acad Sci U S A 107: 15910-15915. doi:10.1073/pnas.1002346107. PubMed: 20733078.
26. Quashie PK, Mesplède T, Han YS, Oliveira M, Singhroy DN, et al. (2012) Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 86: 2696-2705. doi:10.1128/JVI.06591-11. PubMed: 22205735.
27. Cherepanov P, Ambrosio AL, Rahman S, Ellenberger T, Engelman A, (2005) Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc Natl Acad Sci U S A 102: 17308-17313. doi:10.1073/pnas.0506924102. PubMed: 16260736.
28. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242. doi:10.1093/nar/28.1.235. PubMed: 10592235.
29. Steiniger-White M, Rayment I, Reznikoff WS, (2004) Structure/function insights into Tn5 transposition. Curr Opin Struct Biol 14: 50-57. doi:10.1016/j.sbi.2004.01.008. PubMed: 15102449.
30. Johnson BC, Métifiot M, Pommier Y, Hughes SH, (2012) Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity. Antimicrob Agents Chemother 56: 411-419. doi:10.1128/AAC.05292-11. PubMed: 22037850.
31. Grobler JA, Stillmock K, Hu B, Witmer M, Felock P, et al. (2002) Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci U S A 99: 6661-6666. doi:10.1073/pnas.092056199. PubMed: 11997448.
32. Kawasuji T, Yoshinaga T, Sato A, Yodo M, Fujiwara T, et al. (2006) A platform for designing HIV integrase inhibitors. Part 1: 2-hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores. Bioorg Med Chem 14: 8430-8445. doi:10.1016/j.bmc.2006.08.044. PubMed: 17010623.
33. Dicker IB, Terry B, Lin Z, Li Z, Bollini S, et al. (2008) Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors. J Biol Chem 283: 23599-23609. doi:10.1074/jbc.M804213200. PubMed: 18577511.
34. Métifiot M, Maddali K, Naumova A, Zhang X, Marchand C, et al. (2010) Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir. Biochemistry 49: 3715-3722. doi:10.1021/bi100130f. PubMed: 20334344.